Novartis India Stake Sale: Shares Surge 20% on ₹1,446 Crore Deal

Introduction: A Major Ownership Shift

Shares of Novartis India Ltd surged 20% on February 20, 2026, hitting the upper circuit at ₹996.50. The sharp rally followed an announcement from its Swiss parent company, Novartis AG, which confirmed its decision to sell its entire 70.68% stake in the Indian-listed entity. The transaction, valued at approximately ₹1,446 crore, will transfer control to a private equity-led consortium and has triggered a mandatory open offer for public shareholders.

The Transaction Details

Novartis AG has entered into a share purchase agreement to divest its controlling stake, which comprises 1,74,50,680 equity shares. The buyer is a consortium that includes WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners, along with their affiliates. This move marks a complete exit for the Swiss pharmaceutical giant from its listed Indian arm, a decision that follows a strategic review initiated nearly two years ago as part of a broader global restructuring to optimize its portfolio.

The deal signals a significant shift in the company's ownership structure, moving from a multinational corporation's subsidiary to an entity managed by financial investors. This change is expected to bring a new strategic direction to the company's operations in India.

Mandatory Open Offer for Public Shareholders

Under the regulations of the Securities and Exchange Board of India (SEBI), the acquisition of a controlling stake of over 25% triggers a mandatory open offer to public shareholders. This provides minority investors with an opportunity to exit their holdings at a specified price. The consortium has accordingly announced an open offer to acquire an additional 26% of Novartis India's voting share capital.

The offer price has been fixed at ₹860.64 per share, which represents a 3.64% premium over the stock's previous closing price of ₹830.45. The acquirers propose to purchase up to 64,19,608 equity shares from the public, which would amount to a total consideration of ₹552.49 crore if the offer is fully subscribed. The entire consideration is payable in cash.

Market Reaction and Stock Performance

The market responded with strong optimism to the news. Novartis India's stock price immediately locked into its 20% upper circuit, reflecting investor confidence in the deal's valuation and the clarity provided by the open offer. The trading volume for the stock also saw a significant spike.

Despite the recent surge, the stock is still trading about 11% below its 52-week high of ₹1,099.90, which was recorded in May 2025. The stock's 52-week low stands at ₹744.95, hit in March 2025. The recent rally builds on a positive trend, with the stock gaining 22% in the last month and over 14% in the past year.

Key Financials of the Deal

To provide a clear overview, the core financial components of the transaction are summarized below:

Future Under New Ownership

Following the completion of the transaction, Novartis AG will hold no shares in the company and will cease to be its promoter. The acquirers have clarified their intentions regarding the company's future on the stock exchange. They have stated that they do not plan to delist Novartis India and will take necessary steps to comply with the minimum 25% public shareholding requirement if their stake increases beyond the permissible limit after the open offer.

As part of the agreement, Novartis India will undergo a rebranding. The company has agreed to change its name to remove all references to the 'Novartis' brand within 120 days of the deal's closing. This marks a formal end to its association with the Swiss parent and the beginning of a new corporate identity under the PE-led ownership.

Strategic Rationale and Company Outlook

The exit by Novartis AG is consistent with its global strategy of focusing on core markets and high-priority research and development areas. Divesting smaller, listed commercial units in various regions aligns with this portfolio recalibration. Novartis India is primarily engaged in the wholesale distribution of pharmaceuticals and medical goods, and the Swiss parent does not have a manufacturing presence in the country.

For Novartis India, the entry of a private equity consortium could lead to operational restructuring, portfolio expansion, and a renewed focus on growth. The company's recent financial performance showed a 36.8% decline in standalone net profit to ₹16.09 crore for Q3 FY26, on a 7.6% drop in revenue to ₹85.90 crore compared to the previous year. The new ownership may implement strategies to reverse this trend and unlock value.

Conclusion

The sale of Novartis AG's stake in its Indian unit is a landmark transaction that transfers control to a new set of financial investors. The deal provides clarity to the market and an exit opportunity for public shareholders at a premium through the open offer. For Novartis India, it marks the beginning of a new chapter with a fresh strategic direction, a new brand identity, and a continued presence as a listed entity on the Indian stock market.